Caribou Biosciences (CRBU) Change in Accured Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has reported Change in Accured Expenses for 7 consecutive years, with -$2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 14.67% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at -$5.9 million (down 575.75% YoY), while the FY2025 annual figure was -$6.3 million, down 397.09% from the prior year.
• Change in Accured Expenses improved to -$2.6 million in Q1 2026 per CRBU's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.0 million in Q2 2024 and bottomed at -$4.1 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $49647.1 across 5 years, with a median of -$7000.0 in 2022.
• On a YoY basis, Change in Accured Expenses climbed as much as 53057.14% in 2023 and fell as far as 51625.0% in 2023.
• Caribou Biosciences' Change in Accured Expenses stood at $1.0 million in 2022, then surged by 177.3% to $2.9 million in 2023, then tumbled by 176.23% to -$2.2 million in 2024, then slipped by 27.59% to -$2.8 million in 2025, then grew by 6.04% to -$2.6 million in 2026.
• Business Quant data shows CRBU's Change in Accured Expenses at -$2.6 million in Q1 2026, -$2.8 million in Q4 2025, and -$1.1 million in Q3 2025.